Additional file 1 of Transmissible H-aggregated NIR-II fluorophore to the tumor cell membrane for enhanced PTT and synergistic therapy of cancer
Creators: name: Yu, Haoli
name: Wang, Yuesong
name: Chen, Yan
name: Cui, Mengyuan
name: Yang, Fang
name: Wang, Peng
name: Ji, Min
Publisher: name: figshare
Year: 2023
Subjects: Biophysics
Biochemistry
Physical Sciences not elsewhere classified
Medicine
Cell Biology
Pharmacology
Biotechnology
Chemical Sciences not elsewhere classified
Cancer
Computational Biology

description: Additional file 1: Figure S1. Absorption and fluorescence spectra of IALP-C4,RIALP-C4, TIALP-C4 and RRIALP-C4. FigureS2. The H-aggregated state of IR-1061 in the system after running for 90 ns(dash line: distribution layers of IR-1061 in H-aggregated state). (a) Theratio of IR-1061 to DPPG is 1:10. (b) The ratio of IR-1061 to DPPG is 1:20. Figure S3. The linear fitting of − lnθ and time in the cooling curve and photothermal conversionefficiency. (a) IALP-1. (b) IALP-2. (c) IALP-3. (d) IALP-5. (e) Photothermalstability of ICG-ALP (laser on/off for 4 consecutive cycles) irradiated with808 nm laser at 0.3 W/cm2. FigureS4. The photothermal conversion efficiency and photothermal stability ofIR-780-loaded liposomes (phospholipid concentration: 10 mg/mL). (a) The linearfitting of − lnθ and time in the cooling curve andphotothermal conversion efficiency. (b) Photothermal stability of IR-780-loadedliposomes (laser on/off for 4 consecutive cycles) irradiated with 808 nm laserat 0.3 W/cm2. Figure S5. Theabsorption of RRIALP-C4 (phospholipid concentration: 10 mg/mL) after beingirradiated with 808 nm laser (0.3 W/cm2) for different cycles. Figure S6. (a) Thermal images of RRIALP-C4with different phospholipid concentrations after being irradiated with 808 nmlaser at 0.3 W/cm2 in 24-well plates (diluted with cell culturemedium). (b) Temperature changes of RRIALP-C4 with different phospholipid concentrations.Figure S7.Cell viability after drug treatment. (a) ICG aqueoussolution with different concentrations. (b) ICG-loadedliposomes (2% molar content) with different phospholipidconcentrations. Figure S8. In vitro photothermaltherapy and synergistic treatment for A549 cells. (a) Cytotoxicity of A549 cells treated with drugs group (6.7 μM Carbo+1mg/mL IALP-4+L) and single liposomes combi group (1mg/mL ALP-C+1mg/mL IALP+L) aftertreatment for 24 h. (b) Flow cytometry of apoptosis cells treated withdifferent conditions. Q1, Q2, Q3, and Q4 represent necrotic, lateapoptotic, early apoptotic, and viable cells, respectively. (c) Fluorescent staining of dead/living cellstreated with different conditions. Green channel: viable cells. Red channel:dead cells. Figure S9. (a) CLSMimages (100× oil) of A549 cells treated with 2 mg/mL RALP, RRALP, and TRALP for30 min. Blue channel: nucleus. Green channel: cell membrane. Red channel:liposomes. (b) CLSM images (100× oil) of A549 cells treated with 2 mg/mL DALP,RDALP, and TDALP for 30 min. Blue channel: nucleus. Green channel: liposomes.(c) CLSM images (100× oil) of A549 cells treated with 2 mg/mL DRALP, RDRALP,and TDRALP for 30 min. Blue channel: nucleus. Green and red channels:liposomes. Figure S10. Fluorescenceproperties of different phospholipid concentrationsof DiO-ALP and Rhb-ALP. (a) and (b) Excitation and emission spectra of DiO-ALP. (c) Maximum emission peak of DiO-ALP.(d) and (e) Excitation and emission spectra of Rhb-ALP. (f) Maximum emissionpeak of Rhb-ALP. Figure S11. Thermalimages of A549 cells treated with RRIALP-4 (2 mg/mL) in different times (irradiatedwith 808 nm laser at 0.3 W/cm2 for 5 min). Figure S12. Thermal images of A549 cells treated with ICG aqueoussolution and ICG-ALP in different times. (a) Top: ICG aqueous solution (50 μg/mL);Bottom: 2% molar content ICG-ALP (phospholipid concentration: 2 mg/mL). (b) and(c) Temperature change curves of ICG aqueous solution and ICG-ALP. Figure S13. Fluorescence images of A549cells phagocytosis of liposomes. (a) A549 cells treated with DRALP, RRDRALP,and RRDRALP+Pitstop 2 for 30 min. (b) Fluorescence analysis of RhB in A549 cells. Figure S14. (a) In vivo NIR-II FI of RIALP-C4 at different timepoints (0, 1, 3, 6, 12, 24 h). (b) In vivo NIR-II FI of TIALP-C4 at differenttime points (0, 1, 3, 6, 12, 24 h). FigureS15. (a) In vivo PTI of IALP-C4 at different time points (0, 15, 30, 60,90, 120, 180, 240 s). (b) In vivo PTI of RIALP-C4 at different time points (0,15, 30, 60, 90, 120, 180, 240 s). (c) In vivo PTI of TIALP-C4 at different timepoints (0, 15, 30, 60, 90, 120, 180, 240 s). Figure S16. H&amp;E staining sections of organs from differentgroups. Figure S17. In vivo synergistic therapy of RR-ICG-ALP andsingle liosome combi group (RRALP-C+RRIALP-4+L). Figure S18. Absorption peaks of purified cell membrane after Incubated with IALP-4.